Intracoronary Brachytherapy in the Treatment of In-stent Restenosis. Initial Experience in Brazil

Fábio Sândoli de Brito Jr, Rodrigo Hanriot, Breno Oliveira Almeida, Miguel Antonio Neves Rati, Nadia Sueli de Medeiros, Mônica Lagatta, José Carlos da Cruz, João Victor Salvajoli, Marco Antonio Perin

São Paulo, SP - Brazil

Intracoronary brachytherapy using beta or gamma radiation is currently the most efficient type of therapy for preventing the recurrence of coronary in-stent restenosis. Its implementation depends on the interaction among interventionists, radiotherapists, and physicists to assure the safety and quality of the method. The authors report the pioneering experience in Brazil of the treatment of 2 patients with coronary in-stent restenosis, in whom beta radiation was used as part of the international multicenter randomized PREVENT study (Proliferation REduction with Vascular ENergy Trial). The procedures were performed rapidly and did not require significant modifications in the traditional techniques used for conventional angioplasty. Alteration in the radiological protection devices of the hemodynamic laboratory were also not required, showing that intracoronary brachytherapy using beta radiation can be incorporated into the interventional tools of cardiology in our environment.

As a direct consequence of the impressive growth of the number of stents implanted, problems related to restenosis of these metallic endoprostheses have arisen. The incidence of restenosis ranges from 10% to 35% ¹, depending on the population studied, resulting fundamentally from exacerbation of neointimal hyperplasia². Independent of the device used, the treatment of coronary in-stent restenosis is associated with high rates of recurrence (>30%), which may even exceed 50% when the restenosis is long and diffuse ¹-³. More recently, encouraging results from clinical studies using coronary radiotherapy (beta or gamma rays) ⁴-⁷ have introduced new perspectives for the treatment of this problem. The authors report the 2 pioneering cases that introduced this new type of therapy into Brazil.

Case report

Case 1 – The patient is a 53-year-old diabetic, hypertensive, dyslipidemic, male ex-smoker who sought our Service complaining of precordial pain on moderate efforts. He reported using acetylsalicylic acid (200 mg/day), enalapril (20 mg/day), diltiazem (180 mg/day), simvastatin (20 mg/day), glipizide (20 mg/day), and metformin (2 g/day). He also reported having undergone 2 angioplasties in the proximal 1/3 of the circumflex artery, with stent (Multilink Duet 3.5x18 mm) implantation in the latter angioplasty performed in June '99. The physical examination and the electrocardiography performed at the time of hospital admission were normal; a new coronary angiography showed an 80%-obstructing lesion in the initial 1/3 of the circumflex artery at the site of stent implant. The anterior descending and circumflex arteries had only parietal irregularities, and the left ventricle had preserved volume and contractility. In May '00, based on these findings and after signing the written consent, the patient underwent a new angioplasty in the circumflex artery (fig. 1), which was complemented by intracoronary brachytherapy (beta radiation) as part of the international multicenter PREVENT study. The procedure was guided by intracoronary ultrasonography, which showed a reference diameter of the vascular lumen of 3.6 mm, with a large amount of neointimal tissue between the metallic rods of the stent (fig. 1). After progressive dilations with balloon catheters (3.5 and 4.0 x 20 mm), a good angiographic aspect was obtained, with a residual lesion of 20%. The intracoronary echography confirmed the good result of the intervention, and the smallest area of the lumen obtained was 8 mm ². Then, the centralizing perfusion balloon catheter (3.5 x 27 mm) was positioned and inflated (4 atm) in the treated site (figs. 1 and 2), with connection of its distal extremity to the afterloader, which stored the source of beta radiation (³²P) (fig. 2). Then the guidewire (0.018 inches of thickness, and with a radioactive extremity of 27 mm of length) was advanced and positioned (fig. 2) for the application of the dose of 20 Gy at 1 mm from the luminal surface. The total duration of the
application of radiation was 2.5 min. After the intervention, the patient had a good clinical evolution with no electrocardiographic or enzymatic (CKMB) alteration, being discharged on the following day with the same prescriptions as that on admission. On clinical control, 1 month after the procedure, the patient remained free of any symptoms or adverse events. The patient will undergo a late angiographic study (6 months) to assess the efficacy of the treatment used.

**Case 2** - The patient is a 74-year-old diabetic hypertensive female referred to our service due to angina at rest. She was using acetylsalicylic acid (200 mg), propyl nitrate (30 mg), diltiazem (90 mg), chlorpropamide (250 mg), and captopril (37.5 mg) on a daily basis. The patient reported a previous angioplasty with stent implantation in the right coronary and anterior descending coronary arteries, which was performed in January '00. The physical examination did not show significant alterations, but the electrocardiogram showed alterations in ventricular repolarization in the anterior wall (inversion of the T-wave from V1 to V6). Based on these findings, the patient underwent new coronary angiography, which depicted a good angiographic aspect of the stent implanted in the right coronary artery and a 90%-obstructive lesion in the middle 1/3 of the anterior descending coronary artery at the site of the previous implantation of the Multi-link Duet 3.0 x 23 mm stent (in-stent restenosis). After signing the written consent for inclusion in the PREVENT study, the patient underwent a new angioplasty of the anterior descending artery (balloon catheters 3.0x20 and 3.5x15 mm) guided by intracoronary ultrasonography in May '00 (fig. 3). The procedure was successfully performed; a residual lesion of 20% was shown on angiography, and a smaller area of the vascular lumen of 5 mm² was evidenced on intravascular ultrasonography (fig. 3). Then, intracoronary brachytherapy (beta radiation) was performed by positioning and inflation (4 atm) of the centralizing perfusion balloon catheter (3.0 x 27 mm) and progression of the guidewire with a radioactive distal extremity (27 mm) up to the site of the lesion (fig. 2). The prescribed dose of radiation was 20 Gy at 1 mm of the surface of the vascular lumen, and the duration of application (5 min) was based on the measurements of the vascular lumen assessed by intracoronary ultrasonography (diameter of reference of 3.0 mm). The patient had a good
clinical evolution, with no electrocardiographic or enzymatic (CKMB) alteration, and was discharged 2 days after the intervention with the following prescription: acetylsalicylic acid (200 mg/day), diltiazem (90 mg/day), and chlorpropamide (250 mg/day). On clinical control, 1 month after the procedure, the patient was free from anginal symptoms. The patient will undergo a late angiographic study (6 months).

Discussion

Intracoronary brachytherapy is currently the most efficient therapy for preventing recurrence of in-stent restenosis 4-7. Three prospective randomized studies (SCRIPPS, WRIST, and GAMMA-I) using systems based on catheters with gamma radiation showed a 41% to 69% reduction in the rates of angiographic restenosis, associated with a significant reduction in the need for new revascularization of the vessel treated, as compared with isolated angioplasty or angioplasty associated with atheroablative methods 4,6,7. More recently, with the results of the beta-WRIST 5 and START 6 studies, the efficacy of beta radiation in the treatment of in-stent restenosis has been shown. In the randomized START 6 study, a significant reduction occurred in the incidence of angiographic restenosis in patients receiving radiation (28.8% vs 45.2%), with a corresponding reduction in the need for target vessel revascularization (16% vs 24.1%).

Recently, intracoronary brachytherapy was introduced into Brazil as part of a double-blind multicenter prospective and randomized study named PREVENT (Proliferation Reduction with Vascular Energy Trial). Using the prototype of the equipment Galileo™ (Guidant Corporation) (fig. 2), this study assessed the efficacy of brachytherapy (beta radiation; 32P) in the treatment of primary or restenotic lesions, including in-stent restenosis, in native coronary arteries (2.4 to 3.7 mm of diameter). As an inclusion criterion, the authors selected lesions up to 15 mm in length, which allowed that, with a source (guidewire) of 27 mm, their proximal and distal margins could also be irradiated. This therapeutic strategy aims at avoiding the occurrence of restenosis in the margins of the segment treated, which occurs in 8% to 18% of the irradiated cases, and in less than 4% of the control groups. Restenosis in the margins of the segment treated accounts for 33% to 75% of all restenoses following brachytherapy in recent clinical trials 4-7. This phenomenon is caused by the administration of low doses of radiation to sites with a certain degree of vascular trauma produced by the angioplasty balloons or stents (geographic miss), which determines exacerbation of the proliferative process and of the negative remodeling of the arterial wall in these sites 8-9.

As the 2 cases here reported were our first experience, the patients received the irradiation dose prescribed (20 Gy), not requiring the randomization foretold in the study. In these procedures, the use of beta radiation, because of its lower penetration, made possible the safe permanence of the entire professional team inside the room during the procedure, including the interventionists, the radiotherapist, the physicist, and the nursing staff. The duration of application was relatively short, less than 5 min. As the spiral balloon catheter allows distal perfusion, it can remain inflated during this period of time, without causing excessive discomfort to the patients, making possible the centralization of the radioactive source inside the vascular lumen. This centralization of the source is believed to provide a greater homogeneity in the application of the doses of beta radiation in different sites of the vascular wall, even though the disposizioni of the lumen and the atherosclerotic plaques are usually asymmetric.

It is worth noting that, in our 2 reported cases, we tried to optimize the result of the conventional balloon angioplasty, avoiding the implantation of a new stent. This concern is based on the higher risk of the occurrence of late thrombosis when a new stent is implanted in the same procedure in which radiation is applied to the coronary arteries 5-10. In recent studies, the occurrence of late thrombosis (>1 month) has been reported to range from 6% to 15% of the cases treated with beta or gamma radiation; in control groups, it rarely exceeds 2%. 4,7,10,11. Its major cause is the delay in reendothelialization and vascular repair of the lesion 10-12. Aiming at solving this limitation, in addition to avoiding a new stent implantation, we recommend prolonging the regimen of double platelet antiaggregation (acetylsalicylic acid and ticlopidine or clopidogrel) until at least 3 months after the treatment. The efficacy of this approach has been recently confirmed by the results of the START study 6, in which a new stent was implanted in only 21% of the cases, and the platelet antiaggregation was prolonged for up to 60 days, which almost made the late thromboses disappear.

In conclusion, intracoronary brachytherapy using beta radiation is efficient in the adjuvant treatment of coronary in-stent restenosis. Its implementation depends on the interaction of interventionists, radiotherapists, and physicists, reassuring the safety and quality of the method. The application is relatively rapid and does not require expressive modifications of the traditionally used techniques for conventional angioplasty. The solution of its major limitations, such as late thrombosis and restenosis of the margins, should, in the near future, provide the incorporation of this method into the major cardiologic centers of our country, contributing to the progress of interventional cardiology.

* Unpublished data from start trial presented at the meeting of the American College of Cardiology, March 12-15, 2000 in Anaheim, CA, USA.
References